Pulse Explorer nav.journalClub Débats Tendances Chercheurs

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

May 21, 2026

View Full Paper

Safety profile of novel oral poliovirus vaccine type 2

Key Points

To assess the safety profile and immunogenicity of a novel oral poliovirus vaccine type 2.
Randomized trial design
Assessment of vaccine-related adverse events
Evaluation of seroconversion rates post-vaccination
Low incidence of adverse events reported in the vaccine group
High seroconversion rate of 90% in vaccinated individuals
No serious adverse events linked to the novel vaccine type 2

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

A Sat, study studied this question.

synapsesocial.com/papers/6a0ea479be05d6e3efb608fb https://doi.org/https://doi.org/10.1007/s40278-026-94709-0

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

1Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase2026 · 1 citations

Profil de sécurité du nouveau vaccin oral contre le poliovirus de type 2 | Synapse